Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

  1. Sanmarti, R.
  2. Veale, D.J.
  3. Martin-Mola, E.
  4. Escudero-Contreras, A.
  5. González, C.
  6. Ercole, L.
  7. Alonso, R.
  8. Fonseca, J.E.
  9. Alcañiz, C.
  10. Álvaro-Gracia, J.M.
  11. Balsa, A.
  12. de Pablos, J.L.
  13. Miguel, C.D.
  14. Rodríguez, J.M.
  15. Alves, J.
  16. Aurrecoechea, E.
  17. Calvo, J.
  18. Belzunegui, J.
  19. Blanco, F.
  20. Caliz, R.
  21. Calvo, J.
  22. Ivorra, J.R.
  23. Canhão, H.
  24. Santos, H.
  25. Chamizo, E.
  26. del Pino, J.
  27. Delgado, C.
  28. Díaz, C.
  29. Nebro, A.F.
  30. Fraser, A.
  31. Gomez, A.
  32. Hernández, B.
  33. Navarro, F.
  34. Povedano, J.
  35. Mas, A.J.
  36. Kane, D.
  37. Whelan, B.
  38. Marras, C.
  39. Moreno, J.
  40. Venegas, J.P.
  41. Pombo, M.
  42. Riera, E.
  43. Rosas, A.
  44. Ryan, J.
  45. Santos, J.
  46. Santos, M.
  47. Tornero, J.
  48. Tovar, J.V.
  49. Ucar, E.
  50. Vasconcelos, C.
  51. Veiga, R.
  52. Vela, P.
  53. Show all authors +
Journal:
Arthritis and Rheumatology

ISSN: 2326-5205 2326-5191

Year of publication: 2019

Volume: 71

Issue: 10

Pages: 1616-1625

Type: Article

DOI: 10.1002/ART.40905 GOOGLE SCHOLAR

Sustainable development goals